These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35765850)

  • 1. Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A.
    Owaki T; Kamimura K; Ko M; Nagayama I; Nagoya T; Shibata O; Oda C; Morita S; Kimura A; Sato T; Setsu T; Sakamaki A; Kamimura H; Yokoo T; Terai S
    Dis Model Mech; 2022 Jul; 15(7):. PubMed ID: 35765850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver.
    Ko M; Kamimura K; Owaki T; Nagoya T; Sakai N; Nagayama I; Niwa Y; Shibata O; Oda C; Morita S; Kimura A; Inoue R; Setsu T; Sakamaki A; Yokoo T; Terai S
    Dis Model Mech; 2021 Mar; 14(3):. PubMed ID: 33787507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin signals through a gut-liver axis to regulate hepatic steatosis.
    Choi W; Namkung J; Hwang I; Kim H; Lim A; Park HJ; Lee HW; Han KH; Park S; Jeong JS; Bang G; Kim YH; Yadav VK; Karsenty G; Ju YS; Choi C; Suh JM; Park JY; Park S; Kim H
    Nat Commun; 2018 Nov; 9(1):4824. PubMed ID: 30446669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease.
    Nagayama I; Kamimura K; Owaki T; Ko M; Nagoya T; Tanaka Y; Ohkoshi M; Setsu T; Sakamaki A; Yokoo T; Kamimura H; Terai S
    Hepatol Int; 2024 Feb; 18(1):155-167. PubMed ID: 37864724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of LXR signaling by SULT2B1b promotes liver regeneration after partial hepatectomy in mouse models of nonalcoholic fatty liver disease.
    Zhang X; Xu Y; Bai Q; Li X; Han J; Hou Y; Ji Y; Zhang Z
    Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G87-G96. PubMed ID: 32475129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis
    Wang L; Fan X; Han J; Cai M; Wang X; Wang Y; Shang J
    Front Pharmacol; 2020; 11():553. PubMed ID: 32477107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT
    Kim M; Choi W; Yoon J; Jeong BK; Pagire SH; Pagire HS; Park J; Nam JE; Oh CJ; Jeon JH; Kim SS; Lee BH; Song JS; Bae MA; Lee IK; Kim H; Ahn JH
    Eur J Med Chem; 2022 Sep; 239():114517. PubMed ID: 35732081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease.
    Nagoya T; Kamimura K; Inoue R; Ko M; Owaki T; Niwa Y; Sakai N; Setsu T; Sakamaki A; Yokoo T; Kamimura H; Nakamura Y; Ueno M; Terai S
    Neurogastroenterol Motil; 2020 May; 32(5):e13799. PubMed ID: 31984635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
    Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
    J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
    Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
    J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eugenol alleviated nonalcoholic fatty liver disease in rat via a gut-brain-liver axis involving glucagon-like Peptide-1.
    Li H; Yuan W; Tian Y; Tian F; Wang Y; Sun X; Gong Y
    Arch Biochem Biophys; 2022 Aug; 725():109269. PubMed ID: 35508252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation.
    Chen L; Kan J; Zheng N; Li B; Hong Y; Yan J; Tao X; Wu G; Ma J; Zhu W; Sheng L; Chen L; Li B; Zhong J; Du J; Li H
    Phytomedicine; 2021 Oct; 91():153693. PubMed ID: 34403877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.